Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Altus Pharmaceuticals Reports Dosing First Patient In A Phase 2 Trial Of ALTU-238 For Pediatric Growth Hormone Deficiency
Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced that patient dosing in its Phase 2 trial for ALTU-238 in growth hormone deficiency pediatric subjects began on June 2, 2009. ALTU-238 is a long-acting, extended-release formulation of recombinant human growth hormone (rhGH, somatropin), which is being developed utilizing Altus" proprietary protein crystallization technology. ALTU-238 is a ready-to-use liquid suspension of crystallized rhGH that preserves the structure of the rhGH molecule without the need for pegylation, polymerization, or encapsulation and enables administration through a fine gauge needle. The Phase 2 ALTU-238 pediatric trial is being conducted in approximately 18 clinical sites in the U.S. and targets enrolling 36 growth hormone deficient pediatric patients. ALTU-238 has been studied in a series of Phase 1 and Phase 2 studies in healthy and GH deficiency adults.

Expression Of Myoglobin In Human Cancers
A group led by Dr. Alberto Bardelli at The University of Turin Medical School reports that myoglobin may protect against the stresses of tumor growth. This study can be found in the July 2009 issue of the American Journal of Pathology.
News of the day
Interactive Video Games Help Meet Exercise Recommendations
Interactive video games - such those played on the Nintendo Wii - may raise heart rate and provide exercise intensity levels high enough to meet federal physical activity guidelines, according to a pair studies presented at the American College of Sports Medicine"s 56th Annual Meeting in Seattle.
Medical Devices

University Of Rochester Medical Center Receives HANYS' 2009 Community Health Improvement Award

The Healthcare Association of New York State (HANYS) presented its 2009 Community Health Improvement Award to University of Rochester Medical Center for its Health-e- Access (HeA) Telemedicine Network. HANYS established the Community Health Improvement Award in 1997 to recognize outstanding initiatives that improve community health and well-being. The award is presented to facilities and programs that target specific community health issues, demonstrate leadership, collaborate, create partnerships among diverse groups, and achieve quantifiable results. The HeA program has provided telemedicine care and service to children in 23 sites including childcare programs, elementary schools, and a program for severely developmentally disabled children. To date, more than 7,000 telemedicine visits have taken place among children in child-care centers and schools. Ten different physician practices are participating in this initiative, including more than 50 clinicians. 96% of telemedicine visits were successfully completed at the child site, and did not require a follow-up referral to a primary care practice or emergency department. In city child-care centers, absence due to illness dropped by 63% following the introduction of Health-e-Access. In a six-year study, emergency department use was 22% less for children with telemedicine access. Healthcare Association of New York State


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009